Imaging the effect of HSP90 inhibitor AUY922 on HER2 expression by means of 89Zr-trastuzumab PET. A side study to the phase I-II study with AUY922 in either HER2 or ER positive locally advanced or metastatic breast cancer: protocol CAUY922A2101.
Completed
- Conditions
- breast cancermammary carcinoma1001471010006232
- Registration Number
- NL-OMON33851
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 11
Inclusion Criteria
- patients with HER2 positive, trastuzumab (and lapatinib) refractory breast cancer
- participation in the phase I-II trial with HSP90 inhibitor AUY922 (in- and exclusion criteriafor this study with AUY922 are described in protocol CAUY922A2101 -METc 2008.237- section 5.1 and 5.2 (p 37-40).
Exclusion Criteria
- no participation in the phase I-II trial with HSP90 inhibitor AUY922
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Measurement of decreased HER2 expression compared to baseline, as a reflection<br /><br>of response to HSP90 inhibitor AUY922. A decline is defined as at least a 30%<br /><br>decrease of the mean SUV in a maximum of three lesions. These lesions will have<br /><br>a size of at least 2 cm (on the baseline CT), and will show the highest uptake<br /><br>on baseline 89Zr-trastuzumab scan (on which they are predefined). </p><br>
- Secondary Outcome Measures
Name Time Method <p>not applicable</p><br>